Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure
The optimal treatment of patients with diffuse large B-cell lymphoma (DLBCL) or Hodgkin lymphoma (HL) with preexisting cardiomyopathy is uncertain. An anonymous, electronic survey was distributed by e-mail to three US lymphoma cooperative groups, two community hospitals, and twelve academic medical systems, and distributed at one international lymphoma meeting. Fifty hematology-oncology providers caring for patients with lymphoma were included. In response to a vignette of a 67-yo with Stage III DLBCL with LVEF of 40-45%, 15 (30%) would use non-anthracycline regimens, 13 (26%) R-CHOP with liposomal doxorubicin instead of doxorubicin, 11 (22%) R-CHOP without modification and 6 (12%) R-CHOP with a continuous doxorubicin infusion. In a second vignette of a patient with HL in remission after frontline treatment with doxorubicin cumulative dose 300 mg/m<sup>2</sup>, 16 (32%) would order an echocardiogram after treatment. There was substantial variability in preferred treatment regimens with preexisting cardiomyopathy and in cardiac monitoring after anthracycline.
Authors
- Emily R. Anderson (ORCID: https://orcid.org/0000-0003-0387-6166)
- Susan K. Parsons (ORCID: https://orcid.org/0000-0003-0282-6490)
- Matthias Weiss (ORCID: https://orcid.org/0000-0003-2744-0973)
- Richard Kar-Hang Cheng (ORCID: https://orcid.org/0000-0001-5994-5998)
- Rachel J. Buchsbaum (ORCID: https://orcid.org/0000-0003-2502-9240)
- Kathryn J. Ruddy (ORCID: https://orcid.org/0000-0001-6298-332X)
- Urshila Durani (ORCID: https://orcid.org/0000-0003-1860-2424)
- Ana Barac (ORCID: https://orcid.org/0000-0002-9935-8904)
- Jonathan W. Friedberg (ORCID: https://orcid.org/0000-0002-1420-5563)
- Anita Deswal (ORCID: https://orcid.org/0000-0002-6147-9591)
- Yun Young Choi (ORCID: https://orcid.org/0000-0002-6228-6636)
- Daniel J. Landsburg (ORCID: https://orcid.org/0000-0002-5077-4181)
- Anthony F. Yu (ORCID: https://orcid.org/0000-0002-7120-8285)
- Michelle Weisfelner Bloom (ORCID: https://orcid.org/0000-0002-6462-8070)
- Sarju Ganatra (ORCID: https://orcid.org/0000-0003-0296-6864)
- Andreas K. Klein (ORCID: https://orcid.org/0000-0002-2559-8139)
- Andrew M. Evens (ORCID: https://orcid.org/0000-0002-6900-1824)
- Brad S. Kahl (ORCID: https://orcid.org/0000-0003-0459-6609)
- Darryl P. Leong (ORCID: https://orcid.org/0000-0002-1968-169X)
- Eric H. Yang (ORCID: https://orcid.org/0000-0003-4889-7454)
- Jenica Upshaw (ORCID: https://orcid.org/0000-0001-5801-5481)
- Bonnie Ky (ORCID: https://orcid.org/0000-0002-6628-9981)
- Tomas G. Neilan (ORCID: https://orcid.org/0000-0002-1513-8833)
- Aarti H. Asnani (ORCID: https://orcid.org/0000-0003-4967-9918)
Institutions
- Lahey Hospital and Medical Center (US)
- Tufts Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of California, Los Angeles (US)
- Hadassah Medical Center (IL)
- Cancer Institute (WIA) (IN)
- University of Washington Medical Center (US)
- Population Health Research Institute (CA)
- Massachusetts General Hospital (US)
- Hinge Health (US)
- Rutgers Sexual and Reproductive Health and Rights (NL)
- Los Angeles Medical Center (US)
- Regional Cancer Center (US)
- Mayo Clinic in Arizona (US)
- University of Rochester (US)
- Hamilton Health Sciences (CA)
- University of Pennsylvania (US)
- McMaster University (CA)
Publication Details
- Journal
- Leukemia & lymphoma/Leukemia and lymphoma
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1080/10428194.2025.2484367
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00